MBody AI Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Fowler
- Full Time Employees
- 85
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 7111 Syntex Drive Mississauga ON Canada L5N 8C3
- IPO Date
- Feb 19, 2015
- CIK
- 0001610590
- Website
- mbody.ai
- Similar Companies
- Business
- Check-Cap Ltd. (NASDAQ:MBAI) develops and commercializes the C-Scan system, a proprietary capsule-based colorectal cancer screening technology that utilizes ultra-low dose X-rays, an integrated positioning and control system, and software to generate 3D maps of the colon's inner lining for detecting precancerous polyps and structural abnormalities without bowel preparation; the system targets average-risk individuals seeking non-invasive, preparation-free alternatives to traditional colonoscopy to improve screening adherence. Primary products and services encompass the C-Scan disposable capsules, associated hardware for capsule control and recording, and proprietary image analysis software; the technology received CE Mark approval for Europe in 2015 and remains an investigational device in the United States. The company operates in the medical diagnostics industry, serving healthcare providers and patients focused on preventive colorectal cancer screening, with global ambitions centered in Europe, Israel, and the U.S. market pending further regulatory approvals. Founded in 2004 and headquartered at 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, Israel, Check-Cap maintains clinical-stage operations with approximately 85 employees. In a transformative strategic shift, Check-Cap entered into a definitive merger agreement on September 12, 2025, with MBody AI Corp. and its wholly owned subsidiary CC Merger Sub Inc., under which MBody AI will survive as a wholly owned subsidiary of Check-Cap to pivot toward embodied AI-driven automation platforms like the MBody AI Orchestrator for sectors including hospitality, logistics, healthcare, and warehousing; Check-Cap shareholders approved the merger on November 14, 2025, with over 98% support, alongside proposals for a reverse share split (1-for-2 to 1-for-100), director elections, and a name change to MBody AI Ltd. or similar, expecting closure in subsequent weeks subject to customary conditions. This alliance preserves the original exchange ratio despite MBody AI's surged pipeline, multi-year multi-million-dollar contracts with global brands, and heightened institutional interest exceeding hundreds of millions, positioning the combined entity for AI robotics expansion amid projections of trillions in market opportunity by 2030-2050.
Company News
MBody AI Grows Resort Business with Caribe Royale Orlando as New Customer
MBody AI Adds 2 Patents Pending for Its Enterprise AI Workforce Platform
MBody AI Brings Physical AI Robotics Platform to ThinkEquity and Maxim Investors
MBody AI Presents AI Robot Workforce Platform at Lytham Fall 2026 Conference
MBody AI Completes Name Change Following Merger and $10 Million Offering
MBody AI to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MBody AI Advances AI Robotics Rollout at Mohegan Sun
MBody AI Orchestrator Named Finalist for AI Deployment of the Year
Check-Cap Completes MBody AI Merger, Closes $10 Million Underwritten Offering
Check-Cap Ltd. Announces Pricing of $10 Million Public Offering of Ordinary Shares
Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective
Check-Cap Advances MBody AI Merger; Reverse Share Split
Check-Cap Announces Reverse Share Split
Check-Cap: MBody AI Takes Autonomous Services Outdoors, Expanding Addressable Market
Check-Cap (MBAI) Sets Eight-Week Target for MBody AI Merger
Check-Cap (NASDAQ:MBAI) Stock Price Down 1.5% – What’s Next?
Check-Cap: MBody AI Advances Its Robot Fleet Operating System with Multi-Robot Control
Check-Cap (NASDAQ:MBAI) versus Bioventus (NASDAQ:BVS) Financial Survey
Reviewing TransEnterix (OTCMKTS:TRXDW) and Check-Cap (NASDAQ:MBAI)
Check-Cap (NASDAQ:MBAI) and Nanovibronix (NASDAQ:FEED) Head to Head Analysis